menu
    • menu
    [{"orgOrder":0,"company":"Elanco","sponsor":"Neurizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Monepantel","moa":"DEG-3\/DES-2 type nAChR","graph1":"Neurology","graph2":"Phase I","graph3":"Elanco","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Elanco \/ Neurizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Elanco \/ Neurizon Therapeutics"},{"orgOrder":0,"company":"Elanco","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Diclazuril","moa":"||Merozoite","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elanco","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Elanco \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Elanco \/ Merck & Co"},{"orgOrder":0,"company":"Elanco","sponsor":"Kindred Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"KIND-030","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Elanco","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Elanco \/ Elanco","highestDevelopmentStatusID":"10","companyTruncated":"Elanco \/ Elanco"}]

    Find Clinical Drug Pipeline Developments & Deals by Elanco

    Menu

    Elanco

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elanco

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Elanco

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monepantel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Neurizon Therapeutics

                            Deal Size : $79.9 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

                            Details : Elanco is licensing its data and rights regarding monepantel, to Neurizon, which is developing NUZ-001 as a potential treatment for ALS and other neurodegenerative diseases in humans.

                            Product Name : NUZ-001

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 02, 2025

                            Lead Product(s) : Monepantel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Neurizon Therapeutics

                            Deal Size : $79.9 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elanco

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Elanco

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KIND-030

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Kindred Biosciences

                            Deal Size : $16.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal ...

                            Details : The collaboration grants Elanco Animal Health an exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus. Under the agreement, KindredBio also has a right of last refusal to manufacture certain of Elanco's other monoclonal ...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $0.5 million

                            December 11, 2020

                            Lead Product(s) : KIND-030

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Kindred Biosciences

                            Deal Size : $16.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Elanco

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Elanco

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclazuril,Methyl 4-Hydroxybenzoate,Propyl 4-Hydroxybenzoate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Merck & Co

                            Deal Size : $55.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Elanco Signs Agreement with Merck Animal Health

                            Details : Vecoxan joins Elanco’s previously announced Osurnia® and Capstar® divestitures, and divestiture of European Economic Area and U.K.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $55.0 million

                            February 19, 2020

                            Lead Product(s) : Diclazuril,Methyl 4-Hydroxybenzoate,Propyl 4-Hydroxybenzoate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Merck & Co

                            Deal Size : $55.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth